Last $12.46 USD
Change Today -0.20 / -1.58%
Volume 4.9M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 2:15 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$12.61
Previous Close
$12.66
Day High
$12.65
Day Low
$12.46
52 Week High
01/22/14 - $14.08
52 Week Low
08/30/13 - $10.54
Market Cap
16.5B
Average Volume 10 Days
7.8M
EPS TTM
$0.49
Shares Outstanding
1.3B
EX-Date
--
P/E TM
25.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Natick, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation and Asahi INTECC Plan to Develop a New, Differentiated Fractional Flow Reserve Wire

Boston Scientific Corporation and ASAHI INTECC have formalized plans to develop a new, differentiated fractional flow reserve (FFR) wire. The joint project focuses on creating a device intended to improve handling compared to existing FFR wires. The companies have also agreed to collaborate on key enhancements to the Boston Scientific RotaWire(TM) Atherectomy Guidewire. ASAHI INTECC will provide components for the new RotaWire which is designed by Boston Scientific to provide improved control and handling. The RotaWire is a unique 0.009" wire that is used within the Boston Scientific market leading Rotablator(TM) Rotational Atherectomy System to treat calcified lesions in coronary arteries. The introduction of the components manufactured by ASAHI INTECC to advance the RotaWire Atherectomy Guidewire is further evidence of the Boston Scientific commitment to improving products used in the treatment of complex coronary disease.

Vascular Solutions Announces Settlement of Patent Lawsuit with Boston Scientific Corporation

Vascular Solutions Inc. announced that it has reached a settlement of its patent lawsuit with Boston Scientific Corporation relating to patents in the area of coronary guide extension catheters. Vascular Solutions filed the original lawsuit in U.S. District Court for the District of Minnesota in May 2013, alleging that Boston Scientific infringed three patents owned by Vascular Solutions related to rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter. Boston Scientific filed a counterclaim in July 2013, alleging that Vascular Solutions infringed a patent owned by Boston Scientific related to rapid exchange guide extension technology by manufacturing and selling its GuideLiner guide extension catheter. As part of the settlement agreement, all litigation between the two parties related to guide extension will be dismissed.

Boston Scientific Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2014; Revises Earnings Guidance for the Full Year of 2014

Boston Scientific Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $1,873 million compared to $1,809 million a year ago. Operating loss was $69 million compared to operating income of $220 million a year ago. Loss before income taxes was $104 million compared to income before income taxes of $152 million a year ago. Net income was $4 million compared to $130 million a year ago. Adjusted net income pre-tax was $316 million compared to $293 million a year ago. Adjusted net income after-tax was $285 million or $0.21 per diluted share compared to $247 million or $0.18 per diluted share a year ago. For the six months, the company reported net sales of $3,647 million compared to $3,570 million a year ago. Operating income was $128 million compared to operating loss of $109 million a year ago. Income before income taxes was $42 million compared to loss before income taxes of $242 million a year ago. Net income was $137 million or $0.10 per basic and diluted share compared to net loss of $224 million or $0.17 per basic and diluted share a year ago. Adjusted net income pre-tax was $620 million compared to $542 million a year ago. Adjusted net income after-tax was $553 million or $0.41 per diluted share compared to $471 million or $0.35 per diluted share a year ago. The company estimates sales for the third quarter of 2014 in a range of $1.790 to $1.840 billion. The company estimates earnings on a GAAP basis in a range of $0.08 to $0.10 per share. Adjusted earnings, excluding acquisition and divestiture and restructuring-related charges and amortization expense, are estimated in a range of $0.18 to $0.20 per share. The company now estimates revenue for the full year 2014 to be in a range of $7.325 to $7.425 billion (compared to prior guidance of $7.300 to $7.500 billion), which represents growth in a range of 3 to 4% on a reported basis and 3 to 5% on an operational basis. The company now estimates income on a GAAP basis in a range of $0.28 to $0.32 per share (compared to prior guidance of $0.36 to $0.41), and adjusted earnings, excluding intangible asset impairment charges, acquisition and divestiture, litigation, and restructuring-related charges and credits, discrete tax items, and amortization expense, in a range of $0.79 to $0.83 per share (compared to prior guidance of $0.77 to $0.82).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $12.47 USD -0.195

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $117.02 USD -0.51
Coloplast A/S kr465.60 DKK -0.60
Olympus Corp ¥3,655 JPY -40.00
St Jude Medical Inc $64.65 USD +0.10
Terumo Corp ¥2,587 JPY -18.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 70.7x
Price/Sales 2.3x
Price/Book 2.6x
Price/Cash Flow 25.3x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.